Search Result

Results for "

Menin-MLL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (6) Epigenetic Reader Domain (33)
By Research Areas:	Cancer (35) Inflammation/Immunology (2) Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150105

BMF-219 Menin-MLL inhibitor 21	Epigenetic Reader Domain	Inflammation/Immunology Cancer
Menin-MLL inhibitor 21 (example 9) is a specific, irreversible inhibitor of *Menin-MLL* interaction, useful for the study of autoimmune diseases, heteroimmune diseases, cancer, and other diseases dependent on menin-MLL.

HY-148676

Emilumenib Menin-MLL inhibitor 26	Epigenetic Reader Domain	Cancer
Emilumenib (Menin-MLL inhibitor 26) is a *Menin-MLL* inhibitor. Emilumenib also is an active reference. Emilumenib can inhibits cell growth. Emilumenib can be used for the research of leukemia .

HY-15222

Menin-MLL inhibitor MI-2 2 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
Menin-MLL inhibitor MI-2 is a *Menin-MLL* interaction inhibitor with IC₅₀ of 446±28 nM.

HY-128798

Menin-MLL inhibitor 20	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6) .

HY-139076

Menin-MLL inhibitor 19	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .

HY-129167

Menin-MLL inhibitor 4	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity .

HY-156130

Menin-MLL inhibitor 29	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 29 (Compound C1) is a *Menin-MLL* PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a K_D value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC₅₀ value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC₅₀s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth .

HY-P10066

Menin-MLL inhibitor 31	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 31 (compound 18) is a potent inhibitor of the menin MLL interaction with an IC₅₀ value of 4.6 nM .

HY-157814

Menin-MLL inhibitor-25	Apoptosis Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-25 (compound A6) is a potent *Menin-MLL* interaction inhibitor with an IC₅₀ value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest .

HY-163798

Menin-MLL inhibitor 33	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 33 (compound 15-a) is a potent *Menin-MLL* inhibitor with an IC₅₀ value of 3.6 nM. Menin-MLL inhibitor 33 shows antiproliferative activity .

HY-148669

Bleximenib Menin-MLL inhibitor 24	Epigenetic Reader Domain	Cancer
Bleximenib (Menin-MLL inhibitor 24) (compound A) is a **menin-mixed-lineage leukemia 1 (menin-MLL)** inhibitor. Bleximenib can be used for the research of cancer .

HY-15223

MI-3 1 Publications Verification Menin-MLL inhibitor 3	Epigenetic Reader Domain Apoptosis	Cancer
MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity *menin-MLL* inhibitor with an IC₅₀ of 648 nM and a K_d of 201 nM .

HY-151595

Menin-MLL inhibitor-22	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between *menin* and mixed lineage leukemia (MLL) (IC₅₀=7 nM). Menin-MLL inhibitor-22 binds *menin* protein and inhibits cancer cell growth (MV4 cells, IC₅₀=0.3 μM). *Menin* is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) .

HY-148669A

Bleximenib oxalate Menin-MLL inhibitor 24 oxalate	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 24 (compound A) oxalate is a **menin-mixed-lineage leukemia 1 (menin-MLL)** inhibitor, and can be used for the research of cancer .

HY-153714

BN-104 BNM-1192; Menin-MLL inhibitor 27	Epigenetic Reader Domain	Cancer
BN-104 (BNM-1192) is a *menin* inhibitor that inhibits the *menin-MLL* interaction and leads to the degradation of *menin* protein. BN-104 has good antiproliferative activity against three leukemia cell lines with IC₅₀ values of: MV-4-11 AF4 fusion (3.5 nM); MOLM13 AF9 fusion (12 nM); OCI-AML3 NPM1 mutant (11 nM). BN-104 can be used in cancer research, such as acute myeloid leukemia .

HY-148367A

*(1s,4s)-Menin-MLL* inhibitor-23**	Epigenetic Reader Domain	Cancer
(1s,4s)-Menin-MLL inhibitor-23 is the enantiomer of Menin-MLL inhibitor-23 (HY-148367). Menin-MLL inhibitor-23 (Example 99A) is a *menin-MLL* interaction inhibitor .

HY-148669B

(S)-Bleximenib oxalate (S)-Menin-MLL inhibitor 24 oxalate	Epigenetic Reader Domain	Cancer
(S)-Bleximenib ((S)-Menin-MLL inhibitor 24) oxalate is a S-Enantiomer of (S)-Menin-MLL inhibitor 24 oxalate (HY-148669A). (S)-Bleximenib oxalate is a **menin-mixed-lineage leukemia 1 (menin-MLL)** inhibitor, and can be used for the research of cancer .

HY-114162A

VTP50469 fumarate 5 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .

HY-114162

VTP50469 5 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity .

HY-111937

MI-1	Epigenetic Reader Domain	Cancer
MI-1 inhibits *Menin-MLL* interaction with an IC₅₀ of 1.9 μM .

HY-19809

MI-463 1 Publications Verification	Epigenetic Reader Domain	Cancer
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the *menin-mLL* interaction.

HY-16925

MI-503 5+ Cited Publications	Epigenetic Reader Domain	Cancer
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the *menin-mLL* interaction.

HY-133738

M-808	Epigenetic Reader Domain	Cancer
M-808 is a highly potent and efficacious covalent *Menin-MLL* interaction inhibitor, with a binding IC₅₀ value of 2.6 nM .

HY-132234

M-1211	Epigenetic Reader Domain	Cancer
M‑1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression .

HY-132001

Ziftomenib 1 Publications Verification KO-539	Epigenetic Reader Domain	Cancer
Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151) .

HY-160018

BAY-155	Epigenetic Reader Domain	Cancer
BAY-155 is a potent and selective *menin-MLL* tool inhibitor, with an IC₅₀ of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .

HY-108350

MI-2-2	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-134921

MI-nc dihydrochloride	Epigenetic Reader Domain	Cancer
MI-nc dihydrochloride is a weak inhibitor of the *Menin-MLL* fusion protein interaction with an IC₅₀ of 193 μM. MI-nc dihydrochloride can be used as a negative control compound of MI-2 .

HY-19319

MI-136	Epigenetic Reader Domain Androgen Receptor Apoptosis	Cancer
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC₅₀ of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .

HY-117365

MI-1481	Others	Cancer
MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC₅₀ of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .

HY-128347

M‑89	Epigenetic Reader Domain	Inflammation/Immunology Cancer
M-89 is a highly potent and specific *menin* inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia .

HY-136175

Revumenib Maximum Cited Publications 7 Publications Verification SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific *Menin-MLL* inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-124069

M-525	Epigenetic Reader Domain	Cancer
M-525 is a first-in-class, highly potent, irreversible and covalent *menin-MLL* protein-protein interaction inhibitor. M-525 binds to menin with an IC₅₀ of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .

HY-136360

MI-3454 2 Publications Verification	Epigenetic Reader Domain	Cancer
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC₅₀ of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .

HY-117948

ML399	Others	Cancer
ML399 is a second-generation probe optimized for inhibitors of menin-mixed lineage leukemia (MLL) protein-protein interactions. Screening through the Molecular Library Probe Production Network (MLPCN) led to the discovery of several chemical classes, including piperidines, which successfully led to the generation of the first-generation probe ML227. However, metabolic instability, potency, and adjuvant pharmacological activity of ML227 were identified as limiting features. To enhance the utility of menin-MLL inhibitor probes for in vivo mechanistic studies, medicinal chemistry efforts were reinvigorated using a structure-based design approach, which ultimately led to the generation of the announced probe ML399. This study describes the structure-activity relationships and properties of this series of compounds.

Menin-MLL inhibitor 31	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 31 (compound 18) is a potent inhibitor of the menin MLL interaction with an IC₅₀ value of 4.6 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: